Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY-NCBleeding, Thrombosis and Vascular Biology

CO084 | NEW INSIGHTS INTO HEMOPHILIA A: FACTOR VIII–INTEGRIN Β1 PATHWAY AS KEY REGULATOR OF ENDOTHELIAL CELL FUNCTION

Abstract

Background and Aims. Factor VIII (FVIII) is a well-known coagulation factor, and its deficiency causes hemophilia A (HA). Beyond its canonical role in coagulation, FVIII has emerged as a regulator of endothelial cell (EC) biology. However, the molecular mechanisms by which FVIII exert direct effects on EC function remain poorly defined, and the endothelial receptor mediating FVIII-dependent signaling, vascular integrity, and metabolism are still under investigation. The aim of the study is to identify the endothelial surface receptor that binds FVIII and to map the downstream signaling pathways regulating EC function and vascular homeostasis. Methods. Blood outgrowth ECs (BOECs) from HA patients and healthy donors were isolated. FVIII expression in HA-BOECs was restored either by lentiviral vector transduction with a B-domain deleted FVIII (LV-FVIII) or by recombinant FVIII (rhFVIII) treatment. Proteomic profiling of healthy, HA, and LV-FVIII HA-BOECs was assessed. Ligand-receptor interactions were investigated using Flow-TriCEPS technology, co-immunoprecipitation, and immunofluorescence. Functional assays included angiogenesis, migration, permeability, 3D vessel-on-chip models, mitochondrial respirometry, and proliferation. The role of integrin β1 signaling was assessed by shRNA-mediated knockdown and downstream FAK inhibition. Results. Co-immunoprecipitation, colocalization, and shRNA-mediated knockdown studies identified integrin β1 as a key endothelial surface receptor mediating FVIII binding. Engagement of the FVIII–integrin β1 activated intracellular FAK/Src signaling, which was essential for FVIII-driven angiogenesis, migration, and barrier stabilization. In 3D vessel-on-chip models, FVIII-integrin β1 signaling restored vascular integrity and network formation in HA BOECs, whereas integrin β1 silencing abolished these effects. Proteomic profiling revealed dysregulation of pathways related to angiogenesis, extracellular matrix organization, and mitochondrial metabolism in HA-BOECs, all normalized by FVIII reintroduction. Consistently, HA BOECs displayed impaired mitochondrial respiration, ATP production, and reserve respiratory capacity, which were rescued by FVIII in an integrin β1-dependent manner. FVIII deficiency significantly impaired endothelial proliferation, which was restored by either FVIII replacement therapy or gene transfer. However, FVIII signaling was not rescued in HA-BOECs following integrin β1 silencing, supporting the existence of a functional FVIII–integrin β1 signaling axis. Conclusions. FVIII functions as a ligand for integrin β1 on ECs, activating FAK-dependent signaling that governs vascular integrity, proliferation, angiogenesis, and mitochondrial activity. This newly defined FVIII–integrin β1 axis is critical for endothelial homeostasis and provides a mechanistic explanation for endothelial dysfunction in hemophilia A, highlighting novel therapeutic opportunities beyond hemostasis.

Related

  1. The inhibitory effect of gadolinium-conjugated diflunisal on platelet function through regulating outside-in signaling of αIIbβ3 integrin
    Malk Eun Pak, Yeon-Ji Kim, Hado Choi +3
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMCPMCEurope PMC
  2. GClnc1 as an emerging oncogenic regulator with mechanistic insights and clinical implications in human cancers
    Qing Dong, Yixin He, Rui Yu +3
    iSciencePeer-reviewedCC BY 4.0Full textCell biologyOncologyCell PressCrossrefEurope PMC
  3. HDAC6 is a novel regulator of endothelial-to-mesenchymal transition in venous thrombosis
    M. Pilard, V. Gourdou-Latyszenok, L. Gourhant +11
    bioRxivPreprintCC BY-NC-NDFull textPhysiologybioRxiv
  4. Urolithin A and Endothelial and Cerebrovascular Function in Middle-Aged Adults With Obesity : A Randomized Clinical Trial
    Ana Clara da Costa Pinaffi-Langley, Rafal Gulej, Zalan Kaposzta +14
    JAMA network openPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Vascular Phenotyping Across the CKM Syndrome: Arterial Stiffness and Endothelial Function Testing, Prognostic Value and Clinical Implementation
    Cezara-Andreea Gerdanovics, Teodora-Gabriela Alexescu, Cezar Login +13
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{cucci2026co084,
  title = {{CO084 | NEW INSIGHTS INTO HEMOPHILIA A: FACTOR VIII–INTEGRIN Β1 PATHWAY AS KEY REGULATOR OF ENDOTHELIAL CELL FUNCTION}},
  author = {Alessia Cucci},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  month = oct,
  url = {https://www.btvb.org/btvb/article/view/786},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - CO084 | NEW INSIGHTS INTO HEMOPHILIA A: FACTOR VIII–INTEGRIN Β1 PATHWAY AS KEY REGULATOR OF ENDOTHELIAL CELL FUNCTION
AU  - Alessia Cucci
PY  - 2026
DA  - 2026/10/26
JO  - Bleeding, Thrombosis and Vascular Biology
UR  - https://www.btvb.org/btvb/article/view/786
AB  - Background and Aims. Factor VIII (FVIII) is a well-known coagulation factor, and its deficiency causes hemophilia A (HA). Beyond its canonical role in coagulation, FVIII has emerged as a regulator of endothelial cell (EC) biology. However, the molecular mechanisms by which FVIII exert direct effects on EC function remain poorly defined, and the endothelial receptor mediating FVIII-dependent signaling, vascular integrity, and metabolism are still under investigation. The aim of the study is to identify the endothelial surface receptor that binds FVIII and to map the downstream signaling pathways regulating EC function and vascular homeostasis. Methods. Blood outgrowth ECs (BOECs) from HA patients and healthy donors were isolated. FVIII expression in HA-BOECs was restored either by lentiviral vector transduction with a B-domain deleted FVIII (LV-FVIII) or by recombinant FVIII (rhFVIII) treatment. Proteomic profiling of healthy, HA, and LV-FVIII HA-BOECs was assessed. Ligand-receptor interactions were investigated using Flow-TriCEPS technology, co-immunoprecipitation, and immunofluorescence. Functional assays included angiogenesis, migration, permeability, 3D vessel-on-chip models, mitochondrial respirometry, and proliferation. The role of integrin β1 signaling was assessed by shRNA-mediated knockdown and downstream FAK inhibition. Results. Co-immunoprecipitation, colocalization, and shRNA-mediated knockdown studies identified integrin β1 as a key endothelial surface receptor mediating FVIII binding. Engagement of the FVIII–integrin β1 activated intracellular FAK/Src signaling, which was essential for FVIII-driven angiogenesis, migration, and barrier stabilization. In 3D vessel-on-chip models, FVIII-integrin β1 signaling restored vascular integrity and network formation in HA BOECs, whereas integrin β1 silencing abolished these effects. Proteomic profiling revealed dysregulation of pathways related to angiogenesis, extracellular matrix organization, and mitochondrial metabolism in HA-BOECs, all normalized by FVIII reintroduction. Consistently, HA BOECs displayed impaired mitochondrial respiration, ATP production, and reserve respiratory capacity, which were rescued by FVIII in an integrin β1-dependent manner. FVIII deficiency significantly impaired endothelial proliferation, which was restored by either FVIII replacement therapy or gene transfer. However, FVIII signaling was not rescued in HA-BOECs following integrin β1 silencing, supporting the existence of a functional FVIII–integrin β1 signaling axis. Conclusions. FVIII functions as a ligand for integrin β1 on ECs, activating FAK-dependent signaling that governs vascular integrity, proliferation, angiogenesis, and mitochondrial activity. This newly defined FVIII–integrin β1 axis is critical for endothelial homeostasis and provides a mechanistic explanation for endothelial dysfunction in hemophilia A, highlighting novel therapeutic opportunities beyond hemostasis.
SN  - 2785-5309
ER  -